As presented by:

John Svirbely, CMIO and Denis Gagné, CEO & CTO at Trisotech

Targeted drug therapy can be very expensive, and insurance companies do not want to pay for it when it is not indicated. In the second webinar, we will discuss preauthorization for targeted drug therapy using Rituximab as an example. We will show how business models can streamline the appeals process for both the insurer and the provider. Analysis of the data can give insights that can result in process improvements.

View Slides